NCT01168921View on ClinicalTrials.gov

Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL

Enrollment

23

Participants

Timeline

Start Date

November 3, 2010

Primary Completion Date

March 7, 2022

Study Completion Date

March 7, 2022

Conditions

CLLLeukemia

Interventions

DRUG

Eltrombopag

Starting dose 75 mg by mouth (PO) daily for 28 day cycle

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER